Budesonide/formoterol in a single inhaler (Symbicort®) reduces healthcare costs compared with separate inhalers in the treatment of asthma over 12 months
(2003) In International Journal of Clinical Practice 57(8). p.662-667- Abstract
This open, multinational, randomised, parallel-group, six-month extension conducted in the Swedish centres of a previous six-month study compared the costs of a total of 12 months of treatment with budesonide/formoterol in a single inhaler with budesonide plus formoterol separate inhalers in 320 adults with asthma. Patients received budesonide/formoterol (Symbicort® Turbuhaler®) 160/4.5 mg delivered doses, two inhalations b.i.d., or corresponding doses of budesonide (Pulmicort® Turbuhaler) plus formoterol (Oxis® Turbuhaler). Direct costs and indirect costs were estimated. Budesonide/formoterol treatment was associated with reduced healthcare service utilisation and statistically significant reductions in direct (SEK1595, p=0.0004) and... (More)
This open, multinational, randomised, parallel-group, six-month extension conducted in the Swedish centres of a previous six-month study compared the costs of a total of 12 months of treatment with budesonide/formoterol in a single inhaler with budesonide plus formoterol separate inhalers in 320 adults with asthma. Patients received budesonide/formoterol (Symbicort® Turbuhaler®) 160/4.5 mg delivered doses, two inhalations b.i.d., or corresponding doses of budesonide (Pulmicort® Turbuhaler) plus formoterol (Oxis® Turbuhaler). Direct costs and indirect costs were estimated. Budesonide/formoterol treatment was associated with reduced healthcare service utilisation and statistically significant reductions in direct (SEK1595, p=0.0004) and total costs (SEK1884, p=0.043) per person per year compared with budesonice plus formoterol. Budesonide/formoterol reduced the average annual emergency room admission cost per person by SEK489.7 (31% of direct cost reduction) and physician costs by SEK235.4 (15%).The direct cost of study, relief and other medication was reduced by SEK893.8 (47% of total reduction).There were no statistically significant differences in efficacy and safety parameters following treatment with budesonide/formoterol from single or separate inhalers, other than a significantly lower proportion of withdrawals with the single inhaler (9.2% vs 19.4%, p=0.008). In summary, budesonide/formoterol treatment from a single inhaler reduced 12-month treatment costs compared with separate inhalers, while maintaining at least as good control of asthma.
(Less)
- author
- Rosenhall, L. ; Borg, S. LU ; Andersson, H. F. and Ericsson, K.
- publishing date
- 2003-10-01
- type
- Contribution to journal
- publication status
- published
- in
- International Journal of Clinical Practice
- volume
- 57
- issue
- 8
- pages
- 6 pages
- publisher
- Wiley-Blackwell
- external identifiers
-
- scopus:0242490888
- pmid:14627174
- ISSN
- 1368-5031
- language
- English
- LU publication?
- no
- id
- a6449950-3ba3-4b01-a5e2-d60a884965f3
- date added to LUP
- 2018-10-20 11:31:12
- date last changed
- 2024-06-24 22:26:49
@article{a6449950-3ba3-4b01-a5e2-d60a884965f3,
abstract = {{<p>This open, multinational, randomised, parallel-group, six-month extension conducted in the Swedish centres of a previous six-month study compared the costs of a total of 12 months of treatment with budesonide/formoterol in a single inhaler with budesonide plus formoterol separate inhalers in 320 adults with asthma. Patients received budesonide/formoterol (Symbicort® Turbuhaler®) 160/4.5 mg delivered doses, two inhalations b.i.d., or corresponding doses of budesonide (Pulmicort® Turbuhaler) plus formoterol (Oxis® Turbuhaler). Direct costs and indirect costs were estimated. Budesonide/formoterol treatment was associated with reduced healthcare service utilisation and statistically significant reductions in direct (SEK1595, p=0.0004) and total costs (SEK1884, p=0.043) per person per year compared with budesonice plus formoterol. Budesonide/formoterol reduced the average annual emergency room admission cost per person by SEK489.7 (31% of direct cost reduction) and physician costs by SEK235.4 (15%).The direct cost of study, relief and other medication was reduced by SEK893.8 (47% of total reduction).There were no statistically significant differences in efficacy and safety parameters following treatment with budesonide/formoterol from single or separate inhalers, other than a significantly lower proportion of withdrawals with the single inhaler (9.2% vs 19.4%, p=0.008). In summary, budesonide/formoterol treatment from a single inhaler reduced 12-month treatment costs compared with separate inhalers, while maintaining at least as good control of asthma.</p>}},
author = {{Rosenhall, L. and Borg, S. and Andersson, H. F. and Ericsson, K.}},
issn = {{1368-5031}},
language = {{eng}},
month = {{10}},
number = {{8}},
pages = {{662--667}},
publisher = {{Wiley-Blackwell}},
series = {{International Journal of Clinical Practice}},
title = {{Budesonide/formoterol in a single inhaler (Symbicort®) reduces healthcare costs compared with separate inhalers in the treatment of asthma over 12 months}},
volume = {{57}},
year = {{2003}},
}